

ATTORNEYS AT LAW



Robert Greene Stemt Edward J. Kessler Jorge A. Goldstein David K.S. Comwell Robert W. Esmond Tracy-Gene G. Durkin Michael B. Ray Robert E. Sokohl Eric K. Steffe Michael Q. Lee \ Steven R. Ludwig John M. Covert Linda E. Alcorn Robert C. Millonig Lawrence B. Bugaisky Donald J. Featherstor Michael V. Messinger

Judin U. Kim Timothy J. Shea, Jr. Patrick E. Garrett Jeffery T. Helvey* Heidi L. Kraus Crystal D. Sayles Edward W. Yee Albert L. Ferro* Donald R. Banowit Peter A. Jackman Molly A. McCall Teresa U. Medler Jeffrey S. Weaver Kendrick P. Pattersor Vincent L. Capuano Albert J. Fasulo II* Eldora Ellison Floyd W. Russell Swindell homas C. Fiala Brian J. Del Buono Virgil Lee Beaston' Reginald D. Lucas' Kimberly N. Reddick Theodore A. Wood Elizabeth J. Haanes Bruce E. Chalker Joseph S. Ostroff Frank R. Cottlingham' Christine M. Lhulier Rae Lynn Prengaman' Jane Shershenovich' Lawrence J. Carroll' George S. Bardmesser Registered Patent Agents*
Karen R. Markowicz
Andrea J. Kamage
Nancy J. Leith
Joseph M. Conrad III
Ann E. Summerfield
Helene C. Carlson
Gaby L. Longsworth
Matthew J. Dowd
Aaron L. Schwartz
Angelique G. Uy
Boris A. Matvenko
Mary B. Tung
Katrina V. Pel
Bryan L. Skelton
Jason D. Eisenberg

Senior Counsel Samuel L. Fox Kenneth, C. Bass III Lisa A. Dunner

Admitted only in Maryland

*Admitted only in Virginia

*Admitted only in Texas

 Practice Limited to Federal Agencies

July 1, 2002

WRITER'S DIRECT NUMBER: (202) 218-7824 INTERNET ADDRESS: GLONGS@SKGF.COM

Commissioner for Patents Washington, D.C. 20231

Re:

U.S. Utility Patent Application

Appl. No. 09/988,745; Filed: November 20, 2001

For: Human Amine Receptor

Inventors:

LI et al.

Our Ref:

1488.0840002/EKS/GLL

Art Unit:

1646

RECEIVED

JUL 3 2002

TECH CENTER 1600/2900

Sir:

Transmitted herewith for appropriate action are the following documents:

- 1. First Supplemental Information Disclosure Statement;
- 2. PTO Form 1449 citing 1 document;
- 3. A copy of the cited document AT6; and
- 4. One return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

Sterne, Kessler, Goldstein & Fox PLL.C. : 1100 New York Avenue, NW : Washington, DC 20005 : 202.371.2600 f 202.371.2540 : www.skgf.com

Commissioner for Patents July 1, 2002 Page 2

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Galy h. hongsworth

Gaby L. Longsworth

Agent for Applicants Registration No. 47,756

EKS/GLL/eaf Enclosures

SKGF_DC1:30058.1

Sterne, Kessler, Goldstein & Fox PLLC. : 1100 New York Avenue, NW : Washington, DC 20005 : 202.371.2600 f 202.371.2540 : www.skgf.com



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Li et al.

Appl. No. 09/988,745

Filed: November 20, 2001

Human Amine Receptor For:

Confirmation No. 9091

Art Unit: 1646
Examiner: To be assigned

Atty. Docket: 1488.0840002/EKS/GLL

First Supplemental Information Disclosure Statement

RECEIVED

Commissioner for Patents Washington, D.C. 20231

JUL 3 2002

TECH CENTER 1600/2900

Sir:

Listed on accompanying Form PTO-1449 is a document that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this First Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Information Disclosure Statement filed on February 20, 2002 in connection with the above-captioned application. A copy of the document is also provided.

Applicants wish to bring to the attention of the Examiner that SEQ ID NO:1 and the corresponding cDNA clone of this application are related to SEQ ID NO: 9206 in copending U.S. Patent Application Serial No. 09/912,292. A legible copy of the portion of U.S. Patent Application No. 09/912,292 which caused it to be listed on the attached Form PTO-1449 is submitted herewith as Document AT6.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered. This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

This First Supplemental Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

Consideration of the cited document and making the same of record in the prosecution of the above-identified application is respectfully requested. The U.S. Patent and Trademark Office is hereby authorized to charge any tee deticiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Gaby L. Longsworth

Agent for Applicants Registration No. 47,756

Date: July 1, 2002

1100 New York Avenue, N.W. Suite 600 Washington, D.C. 20005-3934 (202) 371-2600

::ODMA\MHODMA\SKGF_DC1;29611;1 SKGF Rev 1/24/02 mac